mRNA Platform Market and Competition Outlook 2025-2030: Virtual Trials Revolutionizing mRNA Development
The mRNA platform market holds significant opportunities, driven by advancements in LNP delivery systems, codon optimization, and synthetic biology tools like CRISPR-Cas9. These innovations support vaccine development, personalized medicine, and treatment for diseases. The rise of virtual trials further facilitates global outreach in drug development.
Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "mRNA Platform Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been added to ResearchAndMarkets.com's offering.
The mRNA Platform Market was valued at USD 7.30 Billion in 2024 and is projected to reach USD 8.93 Billion by 2030, rising at a CAGR of 3.56%.
In September 2023, BioNTech SE partnered with CEPI to accelerate the development of an mRNA-based Mpox vaccine, underscoring the platform's importance in preparing for emerging infectious threats. By mimicking the natural role of RNA in the body, synthetic mRNA sequences are engineered to prompt immune responses or support therapeutic protein production. These technologies are increasingly adopted due to their adaptability, speed of development, and effectiveness, particularly in public health emergencies and personalized medicine applications.
Key Market Drivers: Technological Advancements
Advances in lipid nanoparticle (LNP) delivery systems have enhanced the stability and cellular uptake of mRNA molecules, improving their efficacy. These innovations were instrumental in the success of COVID-19 mRNA vaccines. Modified mRNA sequences are now more stable and less immunogenic, extending vaccine shelf life and easing distribution. For example, Sanofi launched a new mRNA research facility at Griffith University in November 2023 to accelerate drug development.
Techniques like codon optimization are being refined to maximize protein expression, while synthetic biology tools such as CRISPR-Cas9 allow precise mRNA sequence design for targeted therapies. The development of cost-efficient and scalable manufacturing has also improved the availability of mRNA products during global health crises. Furthermore, enhancements in cold chain logistics and stability at varied temperature ranges reduce dependency on ultra-cold storage. The integration of next-generation sequencing supports precise and rapid design of mRNA-based treatments, enabling therapeutic applications across a broad range of indications.
Key Market Challenges: Vaccine Hesitancy and Misinformation
A critical challenge facing the Global mRNA Platform Market is vaccine hesitancy, fueled by misinformation. Despite scientific validation, concerns around safety, efficacy, and long-term impacts have hindered vaccine uptake. Social media platforms are often sources of misinformation, influencing public perception and eroding confidence in mRNA-based vaccines. This hesitancy can reduce immunization rates, hampering efforts to achieve herd immunity and prolonging outbreaks of preventable diseases.
Public mistrust also complicates health campaigns during emergencies, such as pandemics, and may extend skepticism to other public health measures. Low vaccine coverage due to hesitancy not only affects individual health outcomes but also increases pressure on healthcare systems and obstructs disease control efforts at a population level.
Key Market Trends: Increase in the Number of Virtual Trials
The rise of virtual trials is reshaping drug development strategies, including those related to mRNA therapies. Virtual trials use digital platforms for remote data collection, reducing dependence on physical sites and expanding access to more diverse participant populations.
CROs and pharmaceutical companies are increasingly adopting technologies such as telemedicine, wearable sensors, and mobile health apps to monitor patient outcomes in real-time. This approach enhances patient engagement, accelerates trial timelines, and reduces operational costs. The decentralized model is proving particularly effective for vaccines and therapies that require global outreach, supporting rapid data acquisition and streamlined regulatory submissions.
Key Players Profiled in this mRNA Platform Market Report:
AstraZeneca PLC
Asuragen, Inc.
Catalent Pharma Solutions
Arcturus Therapeutics, Inc.
BioNTech AG
CRISPR Therapeutics Inc.
AKESOgen, Inc.
baseclick GmbH
Accent Therapeutics Inc.
Accanis Biotech F&E GmbH & Co KG
Report Scope
In this report, the Global mRNA Platform Market has been segmented into the following categories:
mRNA Platform Market, by Indication:
Autoimmune Diseases
Cancer
Personalized Treatment
Single Cancer Focused
Infectious Diseases
Rare Diseases
Respiratory Diseases
mRNA Platform Market, by Usability:
Prophylactic Vaccines
Therapeutic Drugs
Therapeutic Vaccines
mRNA Platform Market, by mRNA Type:
Nucleoside-Modified mRNA
Self-Amplifying mRNA
Unmodified mRNA
mRNA Platform Market, by End-User:
Hospitals & Clinics
Pharmaceutical Companies
Research Organization
mRNA Platform Market, by Region:
North America
Asia-Pacific
Europe
South America
Middle East & Africa
Key Attributes
Report Attribute
Details
No. of Pages
180
Forecast Period
2024-2030
Estimated Market Value (USD) in 2024
$7.3 Billion
Forecasted Market Value (USD) by 2030
$8.93 Billion
Compound Annual Growth Rate
3.5%
Regions Covered
Global
For more information about this report visit https://www.researchandmarkets.com/r/b5y8hj
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
What eating foods like dark chocolate and berries did to a study group of more than 120,000 people
A new study reveals what drinking tea and eating dark chocolate and berries did for a group of more than 120,000 people. Those foods, as well as fruits like grapes, apples, oranges, and beverages like red wine, all contain flavonoids, which are compounds found in many plant products. Flavonoids can 'help your body function more efficiently while protecting it against everyday toxins and stressors,' per Healthline. The study's authors said those who consumed a diverse range of foods containing flavonoids (such as berries, grapes and dark chocolate) 'could lower their risk of developing serious health conditions and have the potential to live longer,' in a news release. The study has been peer-reviewed. In the study, which was recently published in the journal Nature Food, researchers observed 124,805 participants between the ages of 40 and 70 from the UK Biobank, a large-scale database with biomedical information. The participants were tracked for roughly 10 years and their dietary information was collected using a questionnaire asking them about the frequency in which they ate approximately 200 types of food and 30 beverages. Dr. Benjamin Parmenter, a research fellow at Edith Cowan University in Australia, was the study's first author and co-lead. He said consuming roughly 500 mg of flavonoids a day or more was linked to a 16 per cent lower risk of 'all-cause mortality' (meaning death from any cause). It was also linked to a roughly 10 per cent lower risk of cardiovascular disease, type 2 diabetes, and respiratory disease. A study published in 2025 in peer-reviewed food science journal Foods said, as it pertains to human health, 'flavonoids are recognized for their ability to combat aging, mitigate inflammation, safeguard the nervous system, and promote overall well-being.' However, in another study published in 2022 in the Nutrition Journal, researchers 'observed an increased risk of prostate cancer by higher intake of total flavonoids.' In a study published in 2016 in the Journal of Nutritional Science, researchers called for further studies on flavonoids so their usefulness 'in the diet could be improved for better human health.' 'Over 30 different types of flavonoids are regularly consumed in the human diet. These are found in different types of everyday foods,' Parmenter told National Post over email. A few squares of dark chocolate could be roughly 25 mg of flavonoids. One apple is equal to roughly 100 mg of flavonoids, while one orange is roughly 60 mg. For tea drinkers, one cup of black tea is roughly 300 mg of flavonoids, while the same amount of green tea is roughly 150 mg. 'We observed that consuming a higher quantity and wider diversity of dietary flavonoids, when consumed together, may represent the optimal approach for improving long-term health, compared with increasing either flavonoid quantity or diversity alone,' Parmenter said. Those with the highest flavonoid diversity were more likely to be female, older, have a lower body mass index (BMI), be more physically active and have a higher education and were less likely to be current smokers, according to the study. 'We also know from lab data and clinical studies that different flavonoids work in different ways, some improve blood pressure, others help with cholesterol levels and decrease inflammation,' said study co-lead professor Aedín Cassidy, per the news release. Cassidy is from the Co-Centre for Sustainable Food Systems and Institute for Global Food Security at Queen's University Belfast. The findings of the study show how 'simple and achievable dietary dietary swaps' can 'potentially improve health in the long-term,' she said. 'Dietary swaps, such as drinking more tea and eating more berries and apples for example, can help increase the variety and intake of flavonoid-rich foods, and potentially improve health in the long-term,' said Cassidy. According to researchers, no previous works appear to have reported on the human health benefits of a flavonoid-diverse diet. 'Consequently, replication of our findings in other cohorts and clinical trials will be critical, as will the exploration of flavonoid diversity with other disease outcomes. Interpretation, however, requires careful consideration,' said researchers, in the study. The study was led by researchers from Queen's University Belfast, Edith Cowan University Perth, and the Medical University of Vienna and Universitat Wien. Smoking one cigarette equals 20 minute off your life, study finds What drinking 3 cups of coffee daily did to a study group of more than 170,000 people Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our daily newsletter, Posted, here.
Yahoo
33 minutes ago
- Yahoo
MustGrow Biologics Corp (MGROF) Q1 2025 Earnings Call Highlights: A Promising Start with ...
Sales Revenue: $3.8 million for Q1 2025. Gross Profit: Approximately $540,000. Gross Margin: 14.3%. Cash Position: $2 million. NexusBioAg Sales: Historical sales between $15 million to $20 million, with expectations to maintain this range. Shares Outstanding: 52 million shares, 59 million fully diluted. Warning! GuruFocus has detected 5 Warning Signs with MGROF. Release Date: May 28, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. MustGrow Biologics Corp (MGROF) reported $3.8 million in sales revenue for Q1 2025, marking a significant milestone as their initial sales numbers. The company successfully integrated NexusBioAg, a sales and distribution division, which contributed to the Q1 sales. MustGrow Biologics Corp (MGROF) has a strong partnership with Bayer, which includes a commercial agreement in Europe, Middle East, and Africa, with potential for milestone and royalty payments. The company holds 112 patents, showcasing a robust intellectual property portfolio, and is actively working on new IP generation. MustGrow Biologics Corp (MGROF) is focusing on a high-growth, asset-light model, with a tight capital structure and plans to drive revenue and margin growth. The gross margin for Q1 2025 was 14.3%, which was negatively affected by foreign exchange fluctuations and tariffs. Sales for TerraSante have not yet ramped up significantly, with expectations for more meaningful sales in late 2025 or early 2026. The company faces challenges with the registration process for TerraMG, with potential registration not expected until 2026. MustGrow Biologics Corp (MGROF) is assessing the need for additional working capital to drive revenue growth, indicating potential financial constraints. The agricultural market's seasonality and cyclicality present challenges in sales predictability and revenue generation. Q: Sales so far were all from Canada, right? Were any of them from TerraSante? A: Yes, Q1 sales were all in Canada, specifically through NexusBioAg. TerraSante sales in the US are expected to ramp up in the second half of this year. Q: How have tariffs affected sales, specifically for TerraSante? A: Our products were not directly affected by tariffs, but there were indirect effects such as a weaker Canadian dollar, which negatively impacted margins. Q: Are you able to provide any sort of a forecast for TerraSante? A: No, we do not provide forecasts at this time. Q: Is the regenerative or natural input market for agriculture growing faster than traditional inputs? A: Yes, the regenerative agriculture market is growing at a significant double-digit CAGR compared to the single-digit growth of the synthetic market. Q: When do you expect to see positive free cash flow? A: Our goal is to achieve positive cash flows next year, potentially into 2027, by driving revenues and margins. Q: Do you need more working capital for inventory to drive your revenues? A: Yes, we are assessing access to capital, including non-dilutive options, to support revenue and margin growth. Q: Are there any updates on the registration process for TerraMG? A: In North America, we are progressing with registrations and hope to have them by 2026. Bayer is also working on registrations in Europe, the Middle East, and Africa. Q: Does NexusBioAg only focus on Western Canada, or do they have a presence in Eastern Canada as well? A: NexusBioAg has coverage across Canada, with significant operations in both Western and Eastern Canada. Q: Are there any more impactful products in the pipeline to run through Nexus? A: Yes, there are many products in the pipeline, and we are leveraging Nexus's market access and relationships to introduce them. Q: Is there a push to open up or get approval in more US states? A: Currently, we are focusing on accelerating sales in California, Washington, Oregon, and Idaho, with potential expansion to other states being assessed. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
Quanex Building Products Corp (NX) Q2 2025 Earnings Call Highlights: Record Sales Surge and ...
Net Sales: $452.2 million in Q2 2025, up 70% from $266.2 million in Q2 2024. Net Income: $20.5 million or $0.44 per diluted share in Q2 2025; adjusted net income of $27.9 million or $0.60 per diluted share. Adjusted EBITDA: Increased by 54.7% to $61.9 million in Q2 2025 from $40 million in Q2 2024. North American Fenestration Segment Sales: $151 million in Q2 2025, a decrease of 5.5% from $159.8 million in Q2 2024. European Fenestration Segment Sales: $61.3 million in Q2 2025, up 8.3% from $56.5 million in Q2 2024. North American Cabinet Component Segment Sales: $51.2 million in Q2 2025, compared to $51.1 million in Q2 2024. Tyman Business Sales: $190.1 million in Q2 2025. Cash Flow from Operations: $28.5 million in Q2 2025, compared to $33.1 million in Q2 2024. Free Cash Flow: $13.6 million in Q2 2025. Leverage Ratio: Net debt to last 12 months adjusted EBITDA at 3.2 times; debt covenant leverage ratio at 2.7 times. Share Repurchase: Approximately $23.5 million of stock repurchased in Q2 2025. Cost Synergies: Expected to realize $45 million over time, a 50% increase from the original target. Guidance: Reaffirmed net sales guidance of $1.84 billion to $1.86 billion and adjusted EBITDA guidance of $270 million to $280 million for fiscal 2025. Warning! GuruFocus has detected 3 Warning Signs with NX. Release Date: June 06, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Quanex Building Products Corp (NYSE:NX) reported a significant increase in net sales, reaching $452.2 million in Q2 2025, a 70% rise compared to the same period in 2024, primarily driven by the Tyman acquisition. The integration of the Tyman acquisition is progressing well, with cost synergies expected to reach $45 million, a 50% increase from the original target. The company has successfully localized supply chains to mitigate tariff impacts, with 22% of total cost of goods sold exposed to tariff risk, but USMCA compliance reduces this risk for Mexico and Canada. Quanex Building Products Corp (NYSE:NX) repurchased approximately $23.5 million of its stock in Q2 2025, taking advantage of a low share price and maintaining a healthy balance sheet. The company reaffirmed its net sales guidance of $1.84 billion to $1.86 billion and adjusted EBITDA guidance of $270 million to $280 million for fiscal 2025, indicating confidence in future performance. Despite the overall sales increase, net sales excluding the Tyman contribution declined by 1.4% in Q2 2025, largely due to lower volume in North America. The North American fenestration segment saw a 5.5% decrease in net sales, with volumes declining by approximately 7% year over year. Consumer confidence in North America and Europe is negatively impacted by higher interest rates and geopolitical tensions, affecting market conditions. Pricing pressures continue in Europe, although operational performance has helped offset price concessions. Free cash flow was impacted by one-time items related to integration costs and achieving cost synergies, resulting in $13.6 million for the quarter. Q: Can you give a little more color on raising the synergy target from $30 million to $45 million, and is there potential beyond that? A: George Wilson, CEO, explained that the increase in synergy targets is due to the efficiency and opportunities identified in the new operating segments. These include headcount reductions and sourcing synergies. While revenue synergies are still early, the team is confident in further potential as they continue to refine their strategies. Q: Is the tariff situation an opportunity for Quanex given your domestic manufacturing footprint, and are you seeing bids related to increased domestic sourcing? A: George Wilson, CEO, noted that their structured supply chain and diverse geographic footprint have indeed provided opportunities. They have seen increased quoting and execution of spot purchases, particularly in the cabinet segment, as customers seek to mitigate supply chain risks. Q: Where in the Tyman portfolio have you realized cost synergies faster than expected? A: Scott Zuehlke, CFO, highlighted that the main synergies came from procurement and corporate functions such as finance, HR, and IT. The integration of teams revealed more opportunities than initially estimated. Q: Is the $6.5 million in intangible asset amortization realized in Q2 a good quarterly run rate, and what is the full-year expectation for D&A? A: Scott Zuehlke, CFO, confirmed that the Q2 figure is a reasonable run rate. The company initially guided around $60 million for adjusted D&A for the year, excluding intangible amortization, which remains a good estimate. Q: Can you provide more details on the impact of tariffs on your cost of goods sold? A: George Wilson, CEO, stated that approximately 22% of their total cost of goods sold is exposed to tariff risk, with 13% specific to Mexico and Canada. However, being USMCA compliant, the tariff rate is essentially zero for these countries, minimizing potential margin impacts. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
